![Adobe_668054529 UCB EHSF 2024](/cdn-cgi/image/format=auto/globalassets/learning-zones-and-sponsored-congress/ucb---ehsf-congress-highlights/ucb-ehsf-2024_hero.webp?preset=df)
Advances in hidradenitis suppurativa
Transcript: Short-term treatment landscape and importance of educational activity
Short-term treatment landscape and importance of educational activity
Interview recorded Feb 2024, EHSF 2024. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
Well, I personally think that we get more and more adequate medications for that terrifying disease, so we clearly see we have a huge number of ongoing clinical trials. We have seen very positive results in short-term, but also more and more long-term results. And that's tremendously important to augment the armamentarium of medical options. I think maybe as an expert sometimes you tend to think that everybody should know about the disease, but in the broader medical community, the knowledge about HS is still, I would, say small. So I think it's a very important effort to raise awareness, to bring the disease to the mindset of more medical disciplines, because you can only diagnose what you know and you can only treat what you've diagnosed, so I think that's extremely important.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
This content has been developed independently of the sponsor, UCB Biopharma SRL, which has had no editorial input into the content. EPG Health received funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.